Pharmacokinetics, Safety and Clinical Efficacy of Cannabidiol Treatment of Osteoarthritic Dogs. July 2018
1-The objectives of the study were to determine basic oral pharmacokinetics and assess safety and analgesic of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA).
2- Single-dose administrations were performed using two different doses of CBD enriched (2 mg and 8 mg/kg) oil. The CBD extraction was reconstituted into an olive oil base. A randomized placebo controlled, veterinarian and owner blinded cross over study was conducted. Each dog received each of the two treatments with a 2-week wash-out period.
3- Twenty-two client owned dogs with clinically and radiographically confirmed evidence of osteoarthritis were recruited for the study. Sixteen of these dogs completed the study. Dogs were removed due to osteosarcoma (placebo oil), gastric torsion (placebo oil), prior aggression issues (CBE oil), kidney insufficiency (CBD oil), reoccurring pododermatitis (placebo oil) and diarrhea (placebo oil).
3- At each visit each dog was evaluated by a veterinarian based on a scoring system as well by its owner (canine brief pain inventory and Hudson activity scale) and blood was collected to repeat complete blood counts and chemistry analysis at weeks 2 and 4 for each treatment.
4- Pharmacokinetics demonstrated that CBD half-life of elimination median was 4.2 hours for the 2 mg dose and 4.2 hours for the 8 mg dose.
5- There were no significant difference in subjective veterinary lameness and weightbearing capacity. There were no observed side effects.
To view this clinical trial: www.frontierin.org/articles/10.3389/fvets.2018.00165/full